The FDA has determined that patients with permanent atrial fibrillation who are taking Multaq have an increased the risk of serious cardiovascular events, including death. Their warning stems from two clinical trials, PALLAS and ATHENA that demonstrated this increased risk.
For additional important information about Multaq, go to:
480.905.9208
Toll Free:
1.888.905.9208
February 22, 2012 Middle-Age Grip Strength and Gait Speed May Predict Risk of Dementia and Stroke (2.22.12) According to a recent study middle-aged patients exhibiting stronger grip strength were approximately 40% less...
February 16, 2012 PFCs Tied to Compromised Efficacy of Childhood Vaccinations (2.16.12) PFCs are prolific in our society and can be found in many places such as...
February 16, 2012 Pregnant Women Should Avoid U.S.-Grown Rice Because it May Contain Arsenic (2.16.12) Studies have found that rice grown in the U.S. contains concerning levels of arsenic. The...
February 15, 2012 Beware of Possible Counterfeit Avastin (bevacizumab) (2.15.12) The FDA has issued a warning that counterfeit Avastin 400mg/16mL, may be circulating in the...
February 6, 2012 Fibroids Associated with Higher Risk of Preterm Labor and Other Complications (2.6.12) A small study shows that women found with fibroids at their first ultrasound are at...
January 27, 2012 Proper Diet can Reduce Risk of Developing Diabetes in Childhood and Adulthood (1.27.12) Prior and recent studies demonstrate that a healthy diet and reduced body fat can reduce...